Related Experiment Video

Updated: Apr 27, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

rs2230201 polymorphism may dictate complement C3 levels and response to treatment in chronic hepatitis C patients

S J Chowdhury1, V K Karra, P K Gumma

  • 1Department of Medicine, Maulana Azad Medical College, Delhi University, New Delhi, India; Department of Biotechnology, Gauhati University, Guwahati, India.

Journal of Viral Hepatitis
|July 5, 2014
PubMed

Insights

Serum C3 levels and rs2230201 genotypes impact chronic hepatitis C treatment response. Lower C3 levels and specific genotypes predict poor outcomes, suggesting potential therapeutic targets for sustained virologic response.

Area of Science:

  • Immunology
  • Genetics
  • Hepatology

Background:

  • The predictors of treatment response in chronic hepatitis C (CHC) patients remain incompletely understood.
  • Serum C3 concentration is a key indicator of complement activity, and C3 deficiency is linked to recurrent infections.

Purpose of the Study:

  • To investigate the association between serum C3 levels, C3 functional single nucleotide polymorphisms (SNPs), and treatment response in CHC patients.
  • To determine if C3 genetic variations influence C3 serum levels and impact the achievement of sustained virologic response (SVR).

Main Methods:

  • Serum C3 levels were measured using ELISA in 132 CHC patients and 81 healthy controls.
  • Three functional C3 SNPs, including rs2230201, were genotyped using SSP PCR.
  • Treatment response was assessed in patients receiving Pegylated Interferon + Ribavirin.

Main Results:

  • Healthy individuals exhibited significantly higher serum C3 levels (88.5 ± 19 mg/dL) compared to CHC patients (56 ± 18 mg/dL).
  • The rs2230201 CC genotype was prevalent in responders (33/36), while non-responders predominantly carried non-CC genotypes (9/12).
  • A serum C3 level below 53 mg/dL predicted SVR with 63.89% sensitivity and 66.67% specificity.

Conclusions:

  • The 'C' allele of rs2230201 is associated with elevated serum C3 levels, potentially conferring an advantage for achieving SVR in the homozygous state.
  • Patients with serum C3 levels <53 mg/dL and non-CC genotypes at rs2230201 may have a reduced likelihood of responding to CHC treatment.
  • These findings suggest that C3 levels and rs2230201 genotype could serve as biomarkers for predicting treatment outcomes in CHC.

Keywords:
chronic hepatitis Ccomplement system component 3serum S3 levelstreatment response

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

6.8K
Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

11.2K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
78
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
33
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
380
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
21
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
330